Nicholas Schwab

25PUBLICATIONS
125CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Nanotoxicology, health and safetyInnate immunityGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 26, 2026
Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis.

|Jan 23, 2026
Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.

Tilman Schneider-Hohendorf, Maria Eveslage, Timo Wirth

|Sep 24, 2025
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition.

Regina Berkovich, Tilman Schneider-Hohendorf, Eric Baetscher

|Sep 02, 2025
AhR signaling in skin-resident CD207+ cells is involved in UV-B-induced amelioration of neuroinflammation.

Nadine Mykicki, Johannes A Eble, Heike Weighardt

|Jul 18, 2024
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.

Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk

|Mar 27, 2024
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories.

Catharina C Gross, Andreas Schulte-Mecklenbeck, Olga V Steinberg

Pageof 5

Frequent Collaborators

18 joint publications

Tilman Schneider-Hohendorf

9 joint publications

Andreas Schulte-Mecklenbeck

7 joint publications

Catharina C Gross

6 joint publications

Luisa Klotz